ReviewJournal of personalized medicine2012
Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies.
Review in Journal of personalized medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 66 citations in OpenAlex.
- A comprehensive AMR genotype-phenotype database (CABBAGE).Nucleic acids research · 2026Article
- Precision antimicrobials: the next paradigm shift after broad-spectrum therapy.Frontiers in microbiology · 2026Article
- PATHPOD - A loop-mediated isothermal amplification (LAMP)-based point-of-care system for rapid clinical detection of SARS-CoV-2 in hospitals in Denmark.Sensors and actuators. B, Chemical · 2023Article
- Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19.Frontiers in molecular biosciences · 2023Review
- Metabolomics of infectious diseases in the era of personalized medicine.Frontiers in molecular biosciences · 2023Review
- Open-Source, Adaptable, All-in-One Smartphone-Based System for Quantitative Analysis of Point-of-Care Diagnostics.Diagnostics (Basel, Switzerland) · 2022Article
- Semi-Automated Microfluidic Device Combined with a MiniPCR-Duplex Lateral Flow Dipstick for Screening and Visual Species Identification of Lymphatic Filariae.Micromachines · 2022Article
- Healthcare practice strategies for integrating personalized medicine: Management of COVID-19.World journal of clinical cases · 2021Review
- Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases.Biosensors & bioelectronics · 2021Review
- Biosensor and molecular-based methods for the detection of human coronaviruses: A review.Molecular and cellular probes · 2020Review
- Precision epidemiology for infectious disease control.Nature medicine · 2019Review
- A Comparison of Optical, Electrochemical, Magnetic, and Colorimetric Point-of-Care Biosensors for Infectious Disease Diagnosis.ACS infectious diseases · 2018Review
- An Integrated Care Model With Implementation Roadmap to ImproveFrontiers in public health · 2018Article
- Towards Multiplex Molecular Diagnosis-A Review of Microfluidic Genomics Technologies.Micromachines · 2017Review
- The GenePOC Platform, a Rational Solution for Extreme Point-of-Care Testing.Micromachines · 2016Review
- Diagnostics for Developing Countries.Diagnostics (Basel, Switzerland) · 2015Article
- Real-time duplex applications of loop-mediated AMPlification (LAMP) by assimilating probes.International journal of molecular sciences · 2015Article
- Molecular detection and point-of-care testing in Ebola virus disease and other threats: a new global public health framework to stop outbreaks.Expert review of molecular diagnostics · 2015Review
- Pathogen-Specific Immune Fingerprints during Acute Infection: The Diagnostic Potential of Human γδ T-Cells.Frontiers in immunology · 2014Review
- Highly rapid amplification-free and quantitative DNA imaging assay.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious disease management essentially consists in identifying the microbial cause(s) of an infection, initiating if necessary antimicrobial therapy against microbes, and controlling host reactions to infection. In clinical microbiology, the turnaround time of the diagnostic cycle (>24 hours) often leads to unnecessary suffering and deaths; approaches to relieve this burden include rapid diagnostic procedures and more efficient transmission or interpretation of molecular microbiology results. Although rapid nucleic acid-based diagnostic testing has demonstrated that it can impact on the transmission of hospital-acquired infections, we believe that such life-saving procedures should be performed closer to the patient, in dedicated 24/7 laboratories of healthcare institutions, or ideally at point of care. While personalized medicine generally aims at interrogating the genomic information of a patient, drug metabolism polymorphisms, for example, to guide drug choice and dosage, personalized medicine concepts are applicable in infectious diseases for the (rapid) identification of a disease-causing microbe and determination of its antimicrobial resistance profile, to guide an appropriate antimicrobial treatment for the proper management of the patient. The implementation of point-of-care testing for infectious diseases will require acceptance by medical authorities, new technological and communication platforms, as well as reimbursement practices such that time- and life-saving procedures become available to the largest number of patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.